Amag Falls as Safety Risks Cloud Kidney Drug’s Future

AMAG Pharmaceuticals’ shares fell 21 percent to their lowest in nearly five years after it found ‘life-threatening’ events associated with its key drug, Feraheme, throwing into doubt the drugs future sales.
Finanz Nachrichten